Cosmos Health Showcases Expanding Brand Portfolio at World Health Expo Dubai 2026
Cosmos Health (NASDAQ:COSM) exhibited at World Health Expo Dubai 2026 (Feb 9–12) to showcase its expanding portfolio of proprietary nutraceutical and wellness brands, including Sky Premium Life, NOOR, C-Scrub, and Mediterranation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) exhibited at World Health Expo Dubai 2026 (Feb 9–12) to showcase its expanding portfolio of proprietary nutraceutical and wellness brands, including Sky Premium Life, NOOR, C-Scrub, and Mediterranation.
The company highlighted vertical manufacturing, expanded distribution in Europe, Middle East and North America, and ongoing discussions with potential partners across Asia and Latin America.
Details
News Market Reaction – COSM
On Feb 17, the day this news came out, COSM closed 4.77% below the previous close.
Data tracked by StockTitan Argus for the Feb 17 session.
Key Figures
- Expo visitors
- more than 235,000
- World Health Expo Dubai 2026 attendance
- Expo exhibitors
- over 4,300
- World Health Expo Dubai 2026 participating exhibitors
- Countries represented
- more than 180
- World Health Expo Dubai 2026 international participation
- Current price
- $0.3833
- Pre-news trading level vs 52-week high $1.32 and low $0.2801
- Daily move
- 2.71%
- Price change in the 24h before the article
- 52-week high discount
- 70.96%
- Distance below 52-week high of $1.32
- Shelf registration
- $200,000,000
- Form S-3 shelf capacity for multiple security types
- ATM program
- $100,000,000
- At-the-market common stock offering via A.G.P.
Previous Crypto Reports
-
Expanded Bitcoin holdings to support long-term digital asset strategy.
-
Reported higher customer base, better unit economics, and robotics expansion.
-
Zacks initiated coverage with growth projections and a $4.50 valuation.
-
Cana Laboratories to manufacture PathMuscle under multi‑year volume expectations.
-
Outlined platform strategy, Q3 revenues above $17M, and U.S. manufacturing shift.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nutraceutical medical
antimicrobial medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced its participation in World Health Expo Dubai 2026 (formerly Arab Health), one of the world’s largest and most influential healthcare exhibitions and conferences.
The Expo was held February 9–12, 2026, at the Dubai Exhibition Centre in Expo City Dubai, United Arab Emirates, where Cosmos Health exhibited at Booth SA.A79.
The event, which accommodates more than 235,000 visitors and over 4,300 exhibitors from more than 180 countries, brings together healthcare leaders, distributors, manufacturers, and innovators to explore emerging trends, foster strategic partnerships, and advance international collaboration within the healthcare sector.
At the exhibition, Cosmos Health showcased its growing portfolio of proprietary nutraceutical and wellness brands, led by its flagship Sky Premium Life® line of nutraceuticals, which continues to gain global traction through expanded distribution agreements, new product introductions, and increasing international demand. The brand’s premium formulations have strengthened its presence across the key markets in Europe and the Middle East, while its recent expansion into the North American market through the NOOR line is supported by Cosmos Health’s U.S.-based manufacturing capabilities.
The Company also highlighted several of its other healthcare and consumer brands, including C-Scrub®, its antiseptic wash formulated to deliver reliable antimicrobial properties and support effective hand and skin hygiene, as well as Mediterranation®, its proprietary luxury nutritional supplement line featuring formulations that incorporate organic herbs and plant extracts traditionally sourced from Greece and the broader Mediterranean region, including crataegus, hibiscus, dittany of Crete, oregano, mastic, and kritamos.
The Company’s presence at the Expo provided an opportunity to raise awareness of its vertically integrated manufacturing capabilities and to engage with potential commercial partners, distributors, and industry stakeholders.
Greg Siokas, CEO of Cosmos Health, stated: “Participating in World Health Expo Dubai underscores our commitment to expanding the global footprint of our proprietary brands. Sky Premium Life continues to gain international momentum, and this platform enables us to strengthen strategic relationships, expand distribution opportunities, and showcase the depth and quality of our portfolio. During the exhibition, we held highly productive meetings with participating parties from new regions and territories, ranging from Japan and China to several Latin American countries, and we are currently in the process of advancing several potential agreements. We remain focused on disciplined growth, brand development, and long-term value creation.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/94a84d85-d3b0-4fc8-90ce-e6d6e573c9f1
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.